We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Status Migrainosus - Differentiating Between Responders and Non-responders

This study is currently recruiting participants.
Verified May 2017 by David O'Sullivan, Hartford HealthCare
Sponsor:
ClinicalTrials.gov Identifier:
NCT03066544
First Posted: February 28, 2017
Last Update Posted: May 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
David O'Sullivan, Hartford HealthCare
  Purpose
The main goal of this study is to determine whether it is possible - in the setup of routine clinical care - to identify in individual patients who are clear responders to drug X, common denominators that are absent in individual patients who are non-responders to the same drug, and vice versa. All currently available knowledge about migraine pathophysiology will be utilized, using as much time as is needed to ask as many questions as are necessary, in an attempt to profile clear responders and clear non-responders.

Condition Intervention Phase
Migraine Drug: Bupivacaine Drug: Naratriptan Pill Drug: Dexamethasone Drug: Ketorolac Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This will be a prospective, non-blinded, non-randomized, proof-of-concept study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Status Migrainosus - Differentiating Between Responders and Non-responders in the Setup of Real-life Clinical Practice

Resource links provided by NLM:


Further study details as provided by David O'Sullivan, Hartford HealthCare:

Primary Outcome Measures:
  • time to headache relief [ Time Frame: first week ]
    time to headache relief


Estimated Enrollment: 50
Actual Study Start Date: November 30, 2016
Estimated Study Completion Date: June 30, 2018
Estimated Primary Completion Date: December 31, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: bupivacaine (Exparel)
subjects assigned by clinician's judgment - standard care choice A
Drug: Bupivacaine
Nerve blocks with bupivacaine will be performed at initial visit
Other Name: Exparel
Active Comparator: naratriptan pill (Amerge)
subjects assigned by clinician's judgment - standard care choice B
Drug: Naratriptan Pill
one pill will be administered twice each day for 5 days
Other Name: Amerge
Active Comparator: dexamethasone tablet (Decadron)
subjects assigned by clinician's judgment - standard care choice C
Drug: Dexamethasone
one tablet will be administered twice each day for 3 days
Other Name: Decadron
Active Comparator: ketorolac (Toradol)
subjects assigned by clinician's judgment - standard care choice D
Drug: Ketorolac
ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
Other Name: Toradol

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • males and females
  • ≥18 years old with no upper age limit
  • patients with status migrainosus - defined as a severe migraine headache without aura lasting longer than 72 hours and considered primarily as a complication of migraine
  • patients who are willing and able to provide written, informed consent

Exclusion Criteria:

  • <18 years old
  • unable or unwilling to provide written, informed consent
  • females who are pregnant, breastfeeding, or who are trying to become pregnant
  • patients who do not speak English
  • any medical condition or other reason that in the opinion of the investigators makes the patient unfit or at risk to participate in the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066544


Contacts
Contact: Brooke Pellegrino, PhD (860) 696-2925 Brooke.Pellegrino@hhchealth.org

Locations
United States, Connecticut
Hartford HealthCare Headache Center Recruiting
Wethersfield, Connecticut, United States, 06109
Contact: Brooke Pellegrino, PhD    860-696-2925    Brooke.Pellegrino@hhchealth.org   
Principal Investigator: Brian Grosberg, MD         
Sponsors and Collaborators
Hartford HealthCare
Investigators
Principal Investigator: Brian Grosberg, MD physician
  More Information

Responsible Party: David O'Sullivan, statistician/senior scientist, Hartford HealthCare
ClinicalTrials.gov Identifier: NCT03066544     History of Changes
Other Study ID Numbers: HHC-2016-0221
First Submitted: February 21, 2017
First Posted: February 28, 2017
Last Update Posted: May 11, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by David O'Sullivan, Hartford HealthCare:
migraine
responder
non-responder
treatment

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Dexamethasone acetate
Dexamethasone
Ketorolac
Ketorolac Tromethamine
Bupivacaine
BB 1101
Naratriptan
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anesthetics, Local
Anesthetics
Central Nervous System Depressants